P208 Pathological complete response (PCR) rates after sequential CT in locally advanced BCThe analgesic efficacy of slow release tramadol in the titration phase of treatment of moderate to severe cancer pain has been demonstrated in clinical trials. The aim of the study was to evaluate this ...
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Improvement in Pathological Complete Response (pCR) Rate as Neoadjuvant Therapy Versus Chemotherapy in High-Risk, Early-Stage ER+/HER2- ...
Merck announced that the pivotal Phase 3 KEYNOTE-756 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy met one of its dual primary endpoints of pathological complete respons...
New data from the KEYNOTE-756 trial (NCT03725059) of pembrolizumab (Keytruda; Merck) found that adding the immune checkpoint inhibitor to chemotherapy significantly increased the pathological complete response (pCR) rate and shifted residu...
(2012) The discrepancy between high pathological complete response (pCR) rate and low breast conserving surgery (BCS) following neoadjuvant therapy: analysis ... C Criscitiello,HA Azim,D Agbor-Tarh,... - Congress of the European-society-for-medical-oncology 被引量: 2发表: 2012年 Predictors ...
(pCR) rate in patients with high-risk, early-stage ER+/HER2-breast cancer. Merck. News release. July 28, 2023. Accessed July 28, 2023. https://www.merck.com/news/merck-announces-phase-3-keynote-756-trial-met-primary-endpoint-of-pathological-complete-response-pc...
RESULTS: A basal Ki67 cutpoint of 50% predicted pathological complete response (pCR). Patients with Ki67 >50% achieved a pCR rate of 40% (36 of 91) versus a pCR rate of 19% in patients with Ki67 鈮 50% (33 of 171) (p = .0004). Ki67 predictive value was especially relevant in ...
pCR: Pathological complete response SG: Sacituzumab govitecan SMI: Standardized mitotic index sTILs: Stromal tumor-infiltrating lymphocytes TNBC: Triple-negative breast cancer TROP-2: Trophoblast cell-surface antigen-2 References De Jong, V. M. T.et al.Prognostic value of tumour infiltrating lymphocy...
The group displaying a pathological complete response has higher numbers of (A) CD4 þ , (B) CD8 þ , and (C) FOXP3 þ tumour-infiltrating lymphocytes and (D) higher ratio of CD8 þ /CD4 þ T cells than the non-pCR group. There are no differences in the ratios of (E) ...
The group displaying a pathological complete response has higher numbers of (A) CD4 þ , (B) CD8 þ , and (C) FOXP3 þ tumour-infiltrating lymphocytes and (D) higher ratio of CD8 þ /CD4 þ T cells than the non-pCR group. There are no differences in the ratios of (E) ...